ironic
发表于 2025-3-25 05:28:04
http://reply.papertrans.cn/17/1636/163550/163550_21.png
评论性
发表于 2025-3-25 08:36:46
Conclusions and Future Perspectives,rapies, many of which are undergoing advanced stages of clinical investigation, will probably lead in the next future to the introduction in real life of several other biologics indicated for asthma treatment .
小木槌
发表于 2025-3-25 12:07:51
https://doi.org/10.1007/978-3-8348-9214-0 different responses to pharmacological therapies . The majority of asthmatic patients can achieve a good control of their symptoms using standard treatments including inhaled corticosteroids and bronchodilators such as β.-adrenergic agonists, as well as oral leukotriene inhibitors .
Diatribe
发表于 2025-3-25 18:17:28
https://doi.org/10.1007/978-3-658-30557-4 this key immunological discovery into the approval of the anti-IgE antibody omalizumab for the treatment of severe allergic asthma . Indeed, omalizumab has been the first and for a long time the only biologic drug available in clinical practice for add-on therapy of uncontrolled asthma .
西瓜
发表于 2025-3-25 22:15:23
Wilfried Plaßmann,Detlef Schulzeroids, some subgroups of asthmatic subjects display persistent bronchial and/or blood eosinophilia, associated with an inadequate control of asthma . Therefore, these patients can potentially benefit from additional therapies based on the use of biologic drugs targeting IL-5.
Volatile-Oils
发表于 2025-3-26 00:52:45
http://reply.papertrans.cn/17/1636/163550/163550_26.png
amnesia
发表于 2025-3-26 08:20:12
http://reply.papertrans.cn/17/1636/163550/163550_27.png
最小
发表于 2025-3-26 09:47:47
IL-5-Targeted Antibodies,eroids, some subgroups of asthmatic subjects display persistent bronchial and/or blood eosinophilia, associated with an inadequate control of asthma . Therefore, these patients can potentially benefit from additional therapies based on the use of biologic drugs targeting IL-5.
debase
发表于 2025-3-26 14:31:16
http://reply.papertrans.cn/17/1636/163550/163550_29.png
脱水
发表于 2025-3-26 19:00:20
http://reply.papertrans.cn/17/1636/163550/163550_30.png